天利控股集團(00117.HK)附屬與山東通嘉及青島齊嘉共同成立合營公司 持股40%
格隆匯1月16日丨天利控股集團(00117.HK)公佈,於1月15日,深圳市天農(公司間接全資附屬公司)與山東通嘉及青島齊嘉訂立合營協議,以於中國成立合營公司及有限合夥企業。
根據合營協議,深圳市天農及山東通嘉各自將以人民幣200萬元分別認購合營公司的40%股權,而青島齊嘉(由合營公司管理層成立有限合夥企業)將以人民幣100萬元認購合營公司餘下20%股權。
於合營公司成立後,其將成立有限合夥企業,認購出資總額為人民幣10.01億元,以投資於城市重建、城市發展及基礎建設等有關範疇。
據悉,合營公司將主要從事股權投資管理、投資管理、資產管理及投資諮詢服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.